{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:04:29Z","timestamp":1761919469313},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2011,8,4]],"date-time":"2011-08-04T00:00:00Z","timestamp":1312416000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0020922","type":"journal-article","created":{"date-parts":[[2011,8,4]],"date-time":"2011-08-04T20:55:59Z","timestamp":1312491359000},"page":"e20922","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Extended Interferon-Alpha Therapy Accelerates Telomere Length Loss in Human Peripheral Blood T Lymphocytes"],"prefix":"10.1371","volume":"6","author":[{"given":"Joel M.","family":"O'Bryan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A.","family":"Potts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert L.","family":"Bonkovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuja","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan L.","family":"Rothman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the HALT-C Trial Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2011,8,4]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1101\/gad.1346005","article-title":"Shelterin: the protein complex that shapes and safeguards human telomeres.","volume":"19","author":"T de Lange","year":"2005","journal-title":"Genes Dev"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nri890","article-title":"Telomeres in T and B cells.","volume":"2","author":"RJ Hodes","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.mad.2007.11.005","article-title":"Telomere and adaptive immunity.","volume":"129","author":"NP Weng","year":"2008","journal-title":"Mech Ageing Dev"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1182\/blood.V96.13.4313","article-title":"Interferon alpha down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells.","volume":"96","author":"D Xu","year":"2000","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1089\/jir.1986.6.171","article-title":"The effects of long-term administration of recombinant alpha-2 interferon on lymphocyte subsets, proliferation, and suppressor cell function in multiple sclerosis.","volume":"6","author":"RL Hirsch","year":"1986","journal-title":"J Interferon Res"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1002\/eji.200939444","article-title":"Homeostatic proliferation and survival of naive and memory T cells.","volume":"39","author":"O Boyman","year":"2009","journal-title":"Eur J Immunol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMct061675","article-title":"Peginterferon and ribavirin for chronic hepatitis C.","volume":"355","author":"JH Hoofnagle","year":"2006","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.gastro.2008.09.014","article-title":"Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.","volume":"136","author":"AS Lok","year":"2009","journal-title":"Gastroenterology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa0707615","article-title":"Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.","volume":"359","author":"AM Di Bisceglie","year":"2008","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.cct.2004.08.003","article-title":"Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders.","volume":"25","author":"WM Lee","year":"2004","journal-title":"Control Clin Trials"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1053\/j.gastro.2009.05.007","article-title":"Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial.","volume":"137","author":"JE Everhart","year":"2009","journal-title":"Gastroenterology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/hep.510300526","article-title":"Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States.","volume":"30","author":"MM Jamal","year":"1999","journal-title":"Hepatology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1365-2893.1996.tb00086.x","article-title":"Virus and host factors are both important determinants of response to interferon treatment among patients with chronic hepatitis C.","volume":"3","author":"R Lin","year":"1996","journal-title":"J Viral Hepat"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0753-3322(96)82603-5","article-title":"Alpha interferon treatment of chronic hepatitis C.","volume":"49","author":"R Romeo","year":"1995","journal-title":"Biomed Pharmacother"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/hep.20581","article-title":"Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C.","volume":"41","author":"AL Rothman","year":"2005","journal-title":"Hepatology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/(SICI)1096-9071(199905)58:1<26::AID-JMV4>3.0.CO;2-W","article-title":"Prediction of successful outcome in a randomised controlled trial of the long-term efficacy of interferon alpha treatment for chronic hepatitis C.","volume":"58","author":"C Vandelli","year":"1999","journal-title":"J Med Virol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1055\/s-2005-864784","article-title":"Merging models of hepatitis C virus pathogenesis.","volume":"25","author":"HL Tillmann","year":"2005","journal-title":"Semin Liver Dis"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0140-6736(05)66630-5","article-title":"Obesity, cigarette smoking, and telomere length in women.","volume":"366","author":"AM Valdes","year":"2005","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/j.1651-2227.2008.00783.x","article-title":"Telomere length and obesity.","volume":"97","author":"R Zannolli","year":"2008","journal-title":"Acta Paediatr"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1089\/rej.2008.0819","article-title":"Weight loss in obese men is associated with increased telomere length and decreased abasic sites in rectal mucosa.","volume":"12","author":"NJ O'Callaghan","year":"2009","journal-title":"Rejuvenation Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1038\/nprot.2006.263","article-title":"Flow cytometry and FISH to measure the average length of telomeres (flow FISH).","volume":"1","author":"GM Baerlocher","year":"2006","journal-title":"Nat Protoc"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1126\/science.1147182","article-title":"Telomeric repeat containing RNA and RNA surveillance factors at mammalian chromosome ends.","volume":"318","author":"CM Azzalin","year":"2007","journal-title":"Science"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1742-4933-5-6","article-title":"Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people.","volume":"5","author":"S Koch","year":"2008","journal-title":"Immun Ageing"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"11091","DOI":"10.1073\/pnas.92.24.11091","article-title":"Human naive and memory T lymphocytes differ in telomeric length and replicative potential.","volume":"92","author":"NP Weng","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1152\/physrev.00026.2007","article-title":"Telomeres and aging.","volume":"88","author":"G Aubert","year":"2008","journal-title":"Physiol Rev"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1182\/blood-2002-07-2103","article-title":"Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells.","volume":"101","author":"JM Brenchley","year":"2003","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.4049\/jimmunol.177.8.5145","article-title":"High cytotoxic and specific migratory potencies of senescent CD8+ CD57+ cells in HIV-infected and uninfected individuals.","volume":"177","author":"Y Le Priol","year":"2006","journal-title":"J Immunol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1023\/B:JOCI.0000025447.23473.ab","article-title":"Oligoclonal CD8+ T-cell expansion in patients with chronic hepatitis C is associated with liver pathology and poor response to interferon-alpha therapy.","volume":"24","author":"BJ Manfras","year":"2004","journal-title":"J Clin Immunol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.4049\/jimmunol.160.12.5832","article-title":"T cell renewal rates, telomerase, and telomere length shortening.","volume":"160","author":"RJ De Boer","year":"1998","journal-title":"J Immunol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/nri2449","article-title":"Nutrient sensing and inflammation in metabolic diseases.","volume":"8","author":"GS Hotamisligil","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1189\/jlb.0108028","article-title":"Adipose-immune interactions during obesity and caloric restriction: reciprocal mechanisms regulating immunity and health span.","volume":"84","author":"VD Dixit","year":"2008","journal-title":"J Leukoc Biol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mad.2007.10.010","article-title":"Factors impacting human telomere homeostasis and age-related disease.","volume":"129","author":"D Gilley","year":"2008","journal-title":"Mech Ageing Dev"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"e8612","DOI":"10.1371\/journal.pone.0008612","article-title":"Telomere length trajectory and its determinants in persons with coronary artery disease: longitudinal findings from the heart and soul study.","volume":"5","author":"R Farzaneh-Far","year":"2009","journal-title":"PLoS One"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2741\/3604","article-title":"The emerging role of telomere biology in cardiovascular disease.","volume":"15","author":"J Huzen","year":"2010","journal-title":"Front Biosci"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cca.2009.02.004","article-title":"Association of shorter mean telomere length with risk of incident myocardial infarction: a prospective, nested case-control approach.","volume":"403","author":"RY Zee","year":"2009","journal-title":"Clin Chim Acta"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1084\/jem.20040178","article-title":"Telomere erosion in memory T cells induced by telomerase inhibition at the site of antigenic challenge in vivo.","volume":"199","author":"JR Reed","year":"2004","journal-title":"J Exp Med"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jhep.2010.03.005","article-title":"CD4+ T-lymphocyte telomere length is related to fibrosis stage, clinical outcome and treatment response in chronic hepatitis C virus infection.","volume":"53","author":"M Hoare","year":"2010","journal-title":"J Hepatol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1053\/jhep.2002.36502","article-title":"Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.","volume":"36","author":"A Soza","year":"2002","journal-title":"Hepatology"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s15010-007-7132-6","article-title":"Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.","volume":"36","author":"MG Antonini","year":"2008","journal-title":"Infection"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/hep.24169","article-title":"Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon.","volume":"53","author":"AM Di Bisceglie","journal-title":"Hepatology"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/cncr.23251","article-title":"Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion.","volume":"112","author":"A Hauschild","year":"2008","journal-title":"Cancer"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1517\/17425255.4.8.1111","article-title":"Interferon-beta1b for the treatment of multiple sclerosis.","volume":"4","author":"S Lam","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.cgh.2010.01.022","article-title":"Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial.","volume":"8","author":"A Delgado-Borrego","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/hep.23315","article-title":"Prognostic value of Ishak fibrosis stage: Findings from the hepatitis C antiviral long-term treatment against cirrhosis trial.","volume":"51","author":"JE Everhart","year":"2010","journal-title":"Hepatology"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0020922","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T14:57:17Z","timestamp":1686236237000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0020922"}},"subtitle":[],"editor":[{"given":"Naglaa H.","family":"Shoukry","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2011,8,4]]},"references-count":44,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2011,8,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0020922","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2011,8,4]]}}}